

# ROSELABS FINANCE LIMITED

---

January 21, 2026

To,  
BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai 400 001

**Scrip Code – 531324**

Dear Sir,

**Sub: Newspaper Publication - Un-Audited Financial Results for the quarter and nine months ended December 31, 2025**

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby enclose copies of newspaper publication of the Un-audited Financial Results for the quarter and nine months ended December 31, 2025 as published in the following newspapers:

1. Financial Express
2. Mumbai Lakshadweep

This intimation is also being uploaded on the Company's website at [www.roselabsfinancelimited.in](http://www.roselabsfinancelimited.in)

Kindly take the above information on record.

Thanking you,

Yours truly,

**For Roselabs Finance Limited**

**Gunjan Taunk**  
**Company Secretary and Compliance Officer**  
**Membership No.: A23346**

**Encl: A/a**



## Persistent Systems Limited

Registered Office : Bhageerath, 402, Senapati Bapat Road, Pune 411016, India  
Ph. No. +91(20) 67035555; Fax +91(20) 67036003; Email : info@persistent.com, www.persistent.com, CIN L72300PN1990PLC056696

### Consolidated Audited Statement of Financial Results of Persistent Systems Limited for the quarter and nine months ended December 31, 2025

Sr. No.	Particulars	(₹ in Million)					
		Quarter ended			Nine months ended		Year ended
		December 31, 2025	September 30, 2025	December 31, 2024	December 31, 2025	December 31, 2024	March 31, 2025
<b>Income</b>							
1	Revenue from operations	37,782.05	35,807.20	30,622.84	106,925.12	86,966.05	119,387.17
2	Other income	404.96	517.76	426.34	1,469.34	1,197.94	1,381.54
3	<b>Total income</b>	<b>38,187.01</b>	<b>36,324.96</b>	<b>31,049.18</b>	<b>108,394.46</b>	<b>88,163.99</b>	<b>120,768.71</b>
<b>Expenses</b>							
4	- Employee benefits expense	20,408.56	19,460.96	17,639.37	58,130.89	50,627.08	68,737.17
	- Subcontracting costs	5,597.35	5,374.86	4,331.32	15,768.00	12,804.47	17,491.65
	- Finance costs	189.64	179.79	163.20	540.07	486.67	671.29
	- Depreciation and amortisation expense	1,005.80	1,000.47	821.15	2,944.11	2,278.08	3,069.10
	- Other expenses	4,445.49	4,140.56	3,273.75	12,748.83	8,796.69	12,576.42
	<b>Total expenses</b>	<b>31,646.84</b>	<b>30,156.64</b>	<b>26,228.79</b>	<b>90,131.90</b>	<b>74,992.99</b>	<b>102,545.63</b>
5	<b>Profit before exceptional item and tax</b>	<b>6,540.17</b>	<b>6,168.32</b>	<b>4,820.39</b>	<b>18,262.56</b>	<b>13,171.00</b>	<b>18,223.08</b>
6	<b>Exceptional item</b>	890.25	-	-	890.25	-	-
7	<b>Profit before tax</b>	<b>5,649.92</b>	<b>6,168.32</b>	<b>4,820.39</b>	<b>17,372.31</b>	<b>13,171.00</b>	<b>18,223.08</b>
8	<b>Tax expense</b>	1,404.06	1,710.52	1,388.23	4,460.52	3,437.24	4,721.97
	- Current tax	(148.68)	(256.90)	(297.74)	(446.81)	(310.25)	(500.50)
	- Deferred tax (credit) / charge						
9	<b>Total tax expense</b>	<b>1,255.38</b>	<b>1,453.62</b>	<b>1,090.49</b>	<b>4,013.71</b>	<b>3,126.99</b>	<b>4,221.47</b>
10	<b>Profit for the period / year</b>	<b>4,394.54</b>	<b>4,714.70</b>	<b>3,729.90</b>	<b>13,358.60</b>	<b>10,044.01</b>	<b>14,001.61</b>
<b>A. Items that will not be reclassified to profit or loss</b>							
	- Remeasurements of the defined benefit (liabilities) / asset	(81.15)	74.37	37.57	27.94	207.89	193.08
	- Income tax effect on above	18.92	(17.21)	(9.45)	(7.03)	(52.32)	(49.81)
	<b>(62.23)</b>	<b>57.16</b>	<b>28.12</b>	<b>20.91</b>	<b>155.57</b>	<b>143.27</b>	
<b>B. Items that will be reclassified to profit or loss</b>							
	- Effective portion of cash flow hedge	(72.51)	(931.43)	(367.96)	(840.10)	(414.00)	(34.97)
	- Income tax effect on above	18.25	234.42	86.60	211.44	98.19	8.80
	- Exchange differences in translating the financial statements of foreign operations	242.38	680.76	(357.25)	1,007.68	338.09	81.19
	<b>Total other comprehensive income for the period/year</b>	<b>188.12</b>	<b>(16.25)</b>	<b>(638.61)</b>	<b>379.02</b>	<b>22.28</b>	<b>55.02</b>
	<b>(A+B)</b>	<b>125.89</b>	<b>40.91</b>	<b>(610.49)</b>	<b>399.93</b>	<b>177.85</b>	<b>198.29</b>
11	<b>Total comprehensive income for the period / year (comprising profit and other comprehensive income for the period/year)</b>	<b>4,520.43</b>	<b>4,755.61</b>	<b>3,119.41</b>	<b>13,758.53</b>	<b>10,221.86</b>	<b>14,199.90</b>
12	Paid-up equity share capital (Face value of share ₹ 5 each)	788.75	782.00	779.25	788.75	779.25	779.25
13	Other equity						62,411.40
14	<b>Earnings per equity share (in ₹) (Nominal value of share ₹ 5 each)</b>	28.15	30.31	24.28	85.89	65.56	91.22
	- Basic	27.94	30.15	23.93	85.29	64.82	90.24
15	<b>Dividend per share (in ₹) (Nominal value per share ₹ 5)</b>	22.00	-	20.00	22.00	20.00	20.00
	- Interim dividend	-	-	-	-	-	15.00
	- Final dividend						
	<b>Total dividend per share (face value of ₹ 5 each)</b>	<b>22.00</b>	<b>-</b>	<b>20.00</b>	<b>22.00</b>	<b>20.00</b>	<b>35.00</b>

### 1 Audited standalone financial information

Particulars	(₹ in Million)					
	December 31, 2025	September 30, 2025 (Restated) (Refer Note 7)	December 31, 2024 (Restated) (Refer note 7 & 8)	December 31, 2025	December 31, 2024 (Restated) (Refer note 7 & 8)	March 31, 2025 (Restated) (Refer note 7 & 8)
Revenue from operations	37,185.04	34,929.47	30,016.68	104,695.35	85,404.70	117,280.21
Profit before tax	5,324.54	6,203.51	4,565.92	16,455.98	11,959.15	15,494.20
Profit after tax	3,878.61	4,590.36	3,258.92	12,144.71	8,493.67	11,303.82

### 2 Note for segment information:

Operating segments are components of an enterprise for which discrete financial information is available that is evaluated regularly by the chief operating decision makers, in deciding how to allocate resources and assessing performance. The Group's chief operating decision makers are the Chief Executive Officer and Chairman & Managing Director.

#### Segment revenue, results and capital employed

The operating segments are:

a. Banking, Financial Services and Insurance (BFSI)

b. Healthcare & Life Sciences

c. Software, Hi-Tech and Emerging Industries

(₹ in Million)

Sr. No.	Particulars	Quarter ended			Nine months ended		Year ended
		December 31, 2025	September 30, 2025	December 31, 2024	December 31, 2025	December 31, 2024	March 31, 2025
1	Segment revenue	13,213.17	12,455.60	9,692.28	36,970.21	27,241.24	37,709.68
	- Banking, Financial Services and Insurance	9,604.67	9,027.32	8,483.43	27,058.89	23,859.67	32,551.45
	- Healthcare & Life Sciences	14,964.21	14,324.28	12,447.13	42,896.02	35,865.14	49,126.04
	- Software, Hi-Tech and Emerging Industries						
	<b>Total</b>	<b>37,782.05</b>	<b>35,807.20</b>	<b>30,622.84</b>	<b>106,925.12</b>	<b>86,966.05</b>	<b>119,387.17</b>
2	Less: Inter segment revenue	-	-	-	-	-	-
3	Net sales / income from operations	37,782.05	35,807.20	30,622.84	106,925.12	86,966.05	119,387.17
4	Segment results i.e. profit before tax, interest income, depreciation and amortisation, finance costs, other unallocable expenses and income	4,483.37	4,348.29	3,622.78	12,716.85	9,791.18	13,486.46
	- Banking, Financial Services and Insurance	3,532.12	3,460.10	3,807.64	10,033.71	9,414.89	12,768.39
	- Healthcare & Life Sciences	4,957.47	5,244.33	3,920.07	15,102.17	9,942.73	14,320.53
	- Software, Hi-Tech and Emerging Industries						
	<b>Total</b>	<b>12,972.96</b>	<b>13,052.72</b>	<b>11,150.49</b>	<b>37,852.73</b>	<b>29,148.80</b>	<b>40,575.38</b>
5	Less:						
	- Finance costs	189.64					

